Our highly innovative pipeline is starting to deliver value

	WAVE 1[1]		CLINICAL-STAGE NMEs		WAVE 2[2]			
POTENTIAL APPROVAL	FY21	FY22	FY23	FY24	FY25 and Beyond			
ONCOLOGY	**EXKIVITY**[3] *2L NSCLC with EGFR exon 20 insertion mutation*		**EXKIVITY**[3] *1L NSCLC with EGFR exon 20 insertion mutation*		**modakafusp alfa** *R/R MM* **subasumstat** *Multiple cancers*	**TAK-007** *CD19+ hematologic malignancies* **TAK-605** *Multiple cancers*	**TAK-676** *Solid tumors* **TAK-186** *EGFR Solid Tumor*	**TAK-102** *Multiple cancers* **TAK-940** *CD19+ hematologic malignancies*
RARE GENETICS & HEMATOLOGY	**LIVTENCITY**[3] *R/R CMV infect. in transplant*	**TAK-609**[4] *Hunter CNS (IT)*	**LIVTENCITY**[3] *1L CMV infect. in HSCT* **TAK-755** *cTTP*	**TAK-611** *MLD (IT)*	**pabinafusp alfa**[6] *Hunter Syndrome* **TAK-755** *iTTP, SCD*	**mezagitamab** *MG, ITP* **TAK-607** *Complications of prematurity*		
NEUROSCIENCE			**soticlestat** *DS* **soticlestat** *LGS*		**orexin 2R-ag** *TAK-861/994*[7] *NT1, NT2, IH, Other* **orexin 2R-ag** *TAK-925 Hospital setting*	**TAK-653**[8] *Inadequate resp. in MDD* **TAK-041**[8] *Anhedonia in MDD*	**TAK-341** *Parkinson's Disease* **TAK-071** *Parkinson's Disease*	
GASTRO-ENTEROLOGY	**Eohilia**[5] *EoE Received CRL*				**TAK-999** *AATD Liver Disease* **TAK-906** *Gastroparesis*	**TAK-951** *Nausea & vomiting* **TAK-954** *POGD*	**TAK-105** *Nausea & vomiting* **TAK-510** *Nausea & vomiting*	**TAK-101** *Celiac Disease* **TAK-062** *Celiac Disease* **sibofimloc** *Crohn's Disease (post-op and ileitis)* **TAK-039** *Hepatic encephalopathy*
VACCINES	**TAK-019** *Novavax COVID-19 Vaccine (JP)* **COVID-19 Vaccine** *Moderna Intramuscular Injection (JP)*	**TAK-003** *Dengue Vaccine*			**TAK-426** *Zika Vaccine*			

● U.S. Breakthrough and/or Fast Track Designations
● China Breakthrough and/or Japan SAKIGAKE Designation
Orphan potential in at least one indication
APPROVED
Received Complete Response Letter

1. Potential approval dates depend on data read-outs; some WAVE 1 target approval dates assume accelerated approval
2. Certain WAVE 2 programs may be accelerated into WAVE 1 depending on future data read outs
3. EXKIVITY (brand) – mobocertinib (generic), LIVTENCITY (brand) – maribavir (generic)
4. Filing of TAK-609 is subject to feedback from regulatory agencies on the ongoing extension trial and may change
5. Takeda has received a Complete Response Letter (CRL) from the FDA, and no longer expects approval in FY2021. Takeda is assessing the details of the CRL
6. Partnership with JCR Pharmaceuticals
7. TAK-994 timeline under evaluation
8. Partnership with Neurocrine Biosciences

Takeda's Fiscal Year ends March 31 of the following year; e.g.,"FY21" refers to the twelve-month period ending March 31, 2022.
All timelines are approximate estimates of January 10, 2022. For glossary of disease abbreviations please refer to appendix.

MAXIMIZING THE VALUE OF OUR GLOBAL AND REGIONAL BRANDS

	PHASE 1 & 2	PHASE 3	FILED
ONCOLOGY		**NINLARO®** Proteasome inhibitor Maint. ND MM post-SCT (US, EU) **ICLUSIG®** BCR-ABL inhibitor FL Ph+ ALL (US) **CABOMETYX®** VEGFR/RTK inhibitor mCRPC combo w/atezolizumab (JP) **NINLARO®** Proteasome inhibitor Maint. ND MM no SCT (US, EU, CN) **ALUNBRIG®** ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL) **CABOMETYX®** VEGFR/RTK inhibitor 2L mNSCLC combo w/atezolizumab (JP)	**ALUNBRIG®** ALK inhibitor 1L & 2L ALK+NSCLC (CN) **ADCETRIS®** *Seagen* CD30 ADC CTCL (CN) **NINLARO®** Proteasome inhibitor Maint. ND MM no SCT (JP) **CABOMETYX®** VEGFR/RTK inhibitor 1L RCC combo w/nivolumab (JP)
RARE GENETICS & HEMATOLOGY	**NATPARA®** PTH replacement Hypothyrodism (JP)	**TAKHZYRO®** Anti-kallikrein mAb HAE pediatric (GL) **VONVENDI®** vWF replacement vWD Pediatric on-demand & surgery (GL) **TAKHZYRO®** Anti-kallikrein mAb BMA (GL) **ADYNOVATE®** recombinant Factor VIII Pediatric HemA (EU)	**TAKHZYRO®** Anti-kallikrein mAb HAE (JP) **VONVENDI®** vWF replacement vWD Adult Prophylaxis (GL)
GASTRO-ENTEROLOGY	**ENTYVIO®** α4β7 mAb Pediatric UC/CD (GL)	**ENTYVIO®** α4β7 mAb SubQ CD (US, JP) **VOCINTI®** PCAB H. Pylori (CN) **ENTYVIO®** α4β7 mAb GvHD Prophylaxis (EU, JP) **ALOFISEL®** mesenchymal stem cells Perianal Fistulas in CD (US)	**ENTYVIO®** α4β7 mAb SubQ UC (US, JP) **VOCINTI®** PCAB Reflux Esophagitis Maintenance (CN) **GATTEX®** GLP-2R agonist Pediatric-SBS (JP) **ALOFISEL®** mesenchymal stem cells Perianal Fistulas in CD (JP) **ENTYVIO®** α4β7 mAb Antibiotic-refractory Pouchitis (EU) **TAKECAB®** PCAB Oral disintegrated tablet formulation (JP) **GATTEX®** GLP-2R agonist Adult-SBS (JP)
PDT	**CEPROTIN®** Protein C Concentrate SCPCD (JP)	**CUVITRU®** IgG 20% (human) subcutaneous PID (JP) **HYQVIA®** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase CIDP (US, EU) **HYQVIA®** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US) **HYQVIA®** *Halozyme* IgG 10% + Recombinant Human Hyaluronidase HyHub Device (US)	

● Orphan Drug Designation (in any region / indication for a given asset) ✓ Approved since Q4 FY20

Status as of October 28, 2021; GL = global (USA, Europe, Japan, China). Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas